ClinicalTrials.gg
RecruitingNCT07746726Updated Sep 22, 2026

Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation and Bolus Maintenance in Adults

A Phase 3 interventional study of HRS-9190 and Rocuronium in Neuromuscular Blockade, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study will enroll adult patients scheduled for elective surgery requiring general anesthesia. Participants will be randomly assigned to receive either HRS-9190 for Injection or Rocuronium. The primary objective is to assess the efficacy of HRS-9190 in providing adequate neuromuscular blockade for successful tracheal intubation. Secondary objectives include evaluating the onset time and duration of action following each dose, the total time adequate muscle relaxation is maintained during surgery, and the detailed pattern of neuromuscular recovery. Safety assessments will include monitoring of adverse events, vital signs, laboratory parameters, and other safety indicators throughout the study period. The hypothesis of this study is that HRS-9190 for Injection could provide effective neuromuscular relaxation, with a satisfied safety profile in the target patient population.

02

Conditions studied

  • Neuromuscular Blockade
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written
  2. Subjects requiring elective general anesthesia surgery
  3. Meet specified age and (BMI) criteria
  4. Conform to the ASA Physical Status Classification
  5. Use of highly effective for a specified period if applicable

Exclusion criteria

Exclusion Criteria:

  1. History of significant neuromuscular, cardiovascular, respiratory, or neurological disorders
  2. History of conditions affecting drug metabolism or anesthesia risk
  3. Abnormal laboratory values indicating significant clinical abnormalities
  4. Positive serology for specified infectious diseases
  5. Known to related medications
  6. Recent use of medications interfering with neuromuscular function
  7. History of mental illness, cognitive impairment, or epilepsy
  8. Participation in another clinical trial within a specified period
  9. Any other condition deemed unsuitable by the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    Treatment group A

    Drug: HRS-9190

  • Active comparator
    Treatment group B

    Drug: Rocuronium

Interventions

06

What researchers measure

Primary outcomes

  1. Intubation conditions

    Proportion of subjects with excellent or good intubation conditions as assessed by the Cooper score

    Time frame: Within 5 minutes after administration of the study drug

Secondary outcomes

  1. Time from last dose to recovery from T1% 25% to TOFr ≥90%

    Time from last dose of study drug to recovery from T1% 25% to TOFr ≥90% (minutes)

    Time frame: Within 2 hours after last dose administration

  2. Time to Tracheal Intubation

    Time from administration of study drug to completion of tracheal intubation during the induction period

    Time frame: Within 5 minutes after administration of study drug during induction

  3. Onset Time

    Time from each administration of study drug to maximum suppression of T1%.

    Time frame: Within 30 minutes after each dose of study drug

  4. Duration of Action

    Includes: time from each dose to start of T1% recovery; time to T1% recovery to 10% and 25%; time from last dose to achievement of TOFr 40%, 70%, and 90%

    Time frame: Up to 2 hours after each dose of study drug

  5. Percentage of Time Maintaining Target Neuromuscular Blockade Level

    Proportion of time during which T1% is maintained ≤25% relative to the total drug administration time

    Time frame: Throughout the drug administration period, up to 6 hours

  6. Time to Tracheal Extubation

    Time from the last dose of study drug to removal of the tracheal tube

    Time frame: up to 2 hours after the last dose of study drug

  7. Recovery Index

    Includes: time for T1% recovery from 25% to 75%; time for T1% recovery from 5% to 95%; time from T1% recovery to 10% to achievement of TOFr ≥90%

    Time frame: up to 2 hours after the last dose of study drug

  8. Anesthesiologist's Overall Satisfaction Score

    The overall satisfaction score regarding the quality and ease of neuromuscular management, rated by the attending anesthesiologist using a predefined scale.

    Time frame: Assessed at the end of the surgical procedure, within 1 hour.

  9. Surgeon's Overall Satisfaction Score

    The overall satisfaction score regarding surgical conditions related to muscle relaxation, rated by the operating surgeon using a predefined scale.

    Time frame: Assessed at the end of the surgical procedure, within 1 hour.

07

Study locations

2 of 2 sites recruiting
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410000, China
    Recruiting
    • Yangwen Ou · Principal investigator
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 410000, China
    Recruiting
    • Weifeng Yu · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2026
First posted
Aug 5, 2026
StartActual
Sep 2, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07746726
Responsible party
Sponsor
First posted
Aug 5, 2026
Start date
Sep 2, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 22, 2026

Study contacts

Lei Tang
Contact
lei.tang.lt31@hengrui.com
+0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9190

Start the discussion